Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2012 (2012), Article ID 452902, 13 pages
http://dx.doi.org/10.1155/2012/452902
Research Article

Inhibition of Gene Expression of Organic Cation/Carnitine Transporter and Antioxidant Enzymes in Oxazaphosphorines-Induced Acute Cardiomyopathic Rat Models

Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia

Received 5 February 2012; Revised 12 March 2012; Accepted 29 March 2012

Academic Editor: Felipe Dal-Pizzol

Copyright © 2012 Mohamed M. Sayed-Ahmed et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Shore, “Review of the nitrogen mustards,” Hahnemann Monthly, vol. 82, no. 11, pp. 461–470, 1947. View at Google Scholar · View at Scopus
  2. F. Baumann and R. Preiss, “Cyclophosphamide and related anticancer drugs,” Journal of Chromatography B, vol. 764, no. 1-2, pp. 173–192, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Shanholtz, “Acute life-threatening toxicity of cancer treatment,” Critical Care Clinics, vol. 17, no. 3, pp. 483–502, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. Y. Mythili, P. T. Sudharsan, E. Selvakumar, and P. Varalakshmi, “Protective effect of DL-α-lipoic acid on cyclophosphamide induced oxidative cardiac injury,” Chemico-Biological Interactions, vol. 151, no. 1, pp. 13–19, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. P. Morandi, P. A. Ruffini, G. M. Benvenuto, R. Raimondi, and V. Fosser, “Cardiac toxicity of high-dose chemotherapy,” Bone Marrow Transplantation, vol. 35, no. 4, pp. 323–334, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Katayama, Y. Imai, H. Hashimoto et al., “Fulminant fatal cardiotoxicity following cyclophosphamide therapy,” Journal of Cardiology, vol. 54, no. 2, pp. 330–334, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. V. Todorova, D. Vanderpool, S. Blossom et al., “Oral glutamine protects against cyclophosphamide-induced cardiotoxicity in experimental rats through increase of cardiac glutathione,” Nutrition, vol. 25, no. 7-8, pp. 812–817, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. A. G. Fatani, A. Q. Darweesh, L. Rizwan, A. M. Aleisa, O. A. Al-Shabanah, and M. M. Sayed-Ahmed, “Carnitine deficiency aggravates cyclophosphamide-induced cardiotoxicity in rats,” Chemotherapy, vol. 56, no. 1, pp. 71–81, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. B. A. Mills and R. W. Roberts, “Cyclophosphamide-induced cardiomyopathy. A report of two cases and review of the English literature,” Cancer, vol. 43, no. 6, pp. 2223–2226, 1979. View at Google Scholar · View at Scopus
  10. M. A. Goldberg, J. H. Antin, E. C. Guinan, and J. M. Rappeport, “Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor,” Blood, vol. 86, no. 5, pp. 1114–1118, 1986. View at Google Scholar · View at Scopus
  11. J. S. Gottdiener, F. R. Appelbaum, and V. J. Ferrans, “Cardiotoxicity associated with high-dose cyclophosphamide therapy,” Archives of Internal Medicine, vol. 141, no. 6, pp. 758–763, 1981. View at Publisher · View at Google Scholar · View at Scopus
  12. L. J. Steinherz, P. G. Steinherz, and D. Mangiacasale, “Cardiac changes with cyclophosphamide,” Medical and Pediatric Oncology, vol. 9, no. 5, pp. 417–422, 1981. View at Google Scholar · View at Scopus
  13. A. Nicolini, P. A. Mancini, P. Ferrari et al., “Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC),” Biomedicine and Pharmacotherapy, vol. 58, no. 8, pp. 447–450, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Kandylis, M. Vassilomanolakis, S. Tsoussis, and A. P. Efremidis, “Ifosfamide cardiotoxicity in humans,” Cancer Chemotherapy and Pharmacology, vol. 24, no. 6, pp. 395–396, 1989. View at Google Scholar · View at Scopus
  15. Z. M. N. Quezado, W. H. Wilson, R. E. Cunnion et al., “High-dose ifosfamide is associated with severe, reversible cardiac dysfunction,” Annals of Internal Medicine, vol. 118, no. 1, pp. 31–36, 1993. View at Google Scholar · View at Scopus
  16. C. Buckner, R. Rudolph, A. Fefer et al., “High-dose cyclophosphamide therapy for malignant disease. Toxicity, tumor response, and the effects of stored autologous marrow,” Cancer, vol. 29, pp. 357–365, 1972. View at Google Scholar
  17. M. N. Nagi, O. A. Al-Shabanah, M. M. Hafez, and M. M. Sayed-Ahmed, “Thymoquinone supplementation attenuates cyclophosphamide-induced cardiotoxicity in rats,” Journal of Biochemical and Molecular Toxicology, vol. 25, no. 3, pp. 135–142, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. O. Sehirli, A. Sakarcan, A. Velioglu-Ogunc et al., “Resveratrol improves ifosfamide-induced Fanconi syndrome in rats,” Toxicology and Applied Pharmacology, vol. 222, no. 1, pp. 33–41, 2007. View at Google Scholar
  19. M. M. Sayed-Ahmed, A. Q. Darweesh, and A. J. Fatani, “Carnitine deficiency and oxidative stress provoke cardiotoxicity in an ifosfamide-induced Fanconi Syndrome rat model,” Oxidative Medicine and Cellular Longevity, vol. 3, no. 4, pp. 266–274, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Bremer, “Carnitine. Metabolism and functions,” Physiological Reviews, vol. 63, no. 4, pp. 1420–1480, 1983. View at Google Scholar · View at Scopus
  21. W. H. Kunau, V. Dommes, and H. Schulz, “β-oxidation of fatty acids in mitochondria, peroxisomes, and bacteria: a century of continued progress,” Progress in Lipid Research, vol. 34, no. 4, pp. 267–342, 1995. View at Publisher · View at Google Scholar · View at Scopus
  22. F. M. Vaz and R. J. A. Wanders, “Carnitine biosynthesis in mammals,” Biochemical Journal, vol. 361, no. 3, pp. 417–429, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. I. Tamai, R. Ohashi, J. I. Nezu et al., “Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2,” Journal of Biological Chemistry, vol. 273, no. 32, pp. 20378–20382, 1998. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Maeda, T. Wakasawa, M. Funabashi et al., “Regulation of Octn2 transporter (SLC22A5) by peroxisome proliferator activated receptor alpha,” Biological and Pharmaceutical Bulletin, vol. 31, no. 6, pp. 1230–1236, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. T. M. Visarius, H. Bähler, A. Küpfer, T. Cerny, and B. H. Lauterburg, “Thiodiglycolic acid is excreted by humans receiving ifosfamide and inhibits mitochondrial function in rats,” Drug Metabolism and Disposition, vol. 26, no. 3, pp. 193–196, 1998. View at Google Scholar · View at Scopus
  26. N. P. Marthaler, T. Visarius, A. Küpfer, and B. H. Lauterburg, “Increased urinary losses of carnitine during ifosfamide chemotherapy,” Cancer Chemotherapy and Pharmacology, vol. 44, no. 2, pp. 170–172, 1999. View at Publisher · View at Google Scholar · View at Scopus
  27. T. M. Visarius, J. W. Stucki, and B. H. Lauterburg, “Inhibition and stimulation of long-chain fatty acid oxidation by chloroacetaldehyde and methylene blue in rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 289, no. 2, pp. 820–824, 1999. View at Google Scholar · View at Scopus
  28. F. Graziano, R. Bisonni, V. Catalano et al., “Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients,” British Journal of Cancer, vol. 86, no. 12, pp. 1854–1857, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. M. M. Sayed-Ahmed, “Progression of cyclophosphamide-induced acute renal metabolic damage in carnitine-depleted rat model,” Clinical and Experimental Nephrology, vol. 14, no. 5, pp. 418–426, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. M. M. Sayed-Ahmed, “L-Carnitine attenuates ifosfamide-induced carnitine deficiency and decreased intramitochondrial CoA-SH in rat kidney tissues,” Journal of Nephrology, vol. 24, no. 4, pp. 490–498, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Ciarimboli, S. K. Holle, B. Vollenbröcker et al., “New clues for nephrotoxicity induced by ifosfamide: preferential renal uptake via the human organic cation transporter 2,” Molecular Pharmaceutics, vol. 8, no. 1, pp. 270–279, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. P. Chomczynski, “A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples,” BioTechniques, vol. 15, no. 3, pp. 532–537, 1993. View at Google Scholar · View at Scopus
  33. S. N. Buhl and K. Y. Jackson, “Optimal conditions and comparison of lactate dehydrogenase catalysis of the lactate to pyruvate and pyruvate to lactate reactions in human serum at 25, 30, and 37°C,” Clinical Chemistry, vol. 24, no. 5, pp. 828–831, 1978. View at Google Scholar · View at Scopus
  34. A. H. B. Wu and G. N. Bowers Jr., “Evaluation and comparison of immunoinhibition and immunoprecipitation methods for differentiating MB from BB and macro forms of creatine kinase isoenzymes in patients and healthy individuals,” Clinical Chemistry, vol. 28, no. 10, pp. 2017–2021, 1982. View at Google Scholar · View at Scopus
  35. J. A. Prieto, F. Andrade, L. Aldámiz-Echevarría, and P. Sanjurjo, “Determination of free and total carnitine in plasma by an enzymatic reaction and spectrophotometric quantitation spectrophotometric determination of carnitine,” Clinical Biochemistry, vol. 39, no. 10, pp. 1022–1027, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. W. Heuberger, S. Berardi, E. Jacky, P. Pey, and S. Krähenbühl, “Increased urinary excretion of carnitine in patients treated with cisplatin,” European Journal of Clinical Pharmacology, vol. 54, no. 7, pp. 503–508, 1998. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Mancinelli, S. D'Iddio, R. Bisonni, F. Graziano, P. Lippe, and M. Calvani, “Urinary excretion of l-carnitine and its short-chain acetyl-l-carnitine in patients undergoing carboplatin treatment,” Cancer Chemotherapy and Pharmacology, vol. 60, no. 1, pp. 19–26, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Haschke, T. Vitins, S. Lüde et al., “Urinary excretion of carnitine as a marker of proximal tubular damage associated with platin-based antineoplastic drugs,” Nephrology Dialysis Transplantation, vol. 25, no. 2, pp. 426–433, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. R. R. Ramsay, R. D. Gandour, and F. R. van der Leij, “Molecular enzymology of carnitine transfer and transport,” Biochimica et Biophysica Acta, vol. 1546, no. 1, pp. 21–43, 2001. View at Publisher · View at Google Scholar · View at Scopus
  40. A. M. Lamhonwah, J. Skaug, S. W. Scherer, and I. Tein, “A third human carnitine/organic cation transporter (OCTN3) as a candidate for the 5q31 Crohn's disease locus (IBD5),” Biochemical and Biophysical Research Communications, vol. 301, no. 1, pp. 98–101, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. W. Xuan, A. M. Lamhonwah, C. Librach, K. Jarvi, and I. Tein, “Characterization of organic cation/carnitine transporter family in human sperm,” Biochemical and Biophysical Research Communications, vol. 306, no. 1, pp. 121–128, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. P. Abraham and S. Rabi, “Nitrosative stress, protein tyrosine nitration, PARP activation and NAD depletion in the kidneys of rats after single dose of cyclophosphamide,” Clinical and Experimental Nephrology, vol. 13, no. 4, pp. 281–287, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. M. E. Ganapathy, W. Huang, D. P. Rajan et al., “β-Lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter,” Journal of Biological Chemistry, vol. 275, no. 3, pp. 1699–1707, 2000. View at Publisher · View at Google Scholar · View at Scopus
  44. C. A. Wagner, U. Lükewille, S. Kaltenbach et al., “Functional and pharmacological characterization of human Na+-carnitine cotransporter hOCTN2,” American Journal of Physiology, vol. 279, no. 3, pp. F584–F591, 2000. View at Google Scholar · View at Scopus
  45. M. M. Sayed-Ahmed, O. A. Al-Shabanah, M. M. Hafez, A. M. Aleisa, and S. S. Al-Rejaie, “Inhibition of gene expression of heart fatty acid binding protein and organic cation/carnitine transporter in doxorubicin cardiomyopathic rat model,” European Journal of Pharmacology, vol. 640, no. 1–3, pp. 143–149, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. Y. A. Asiri, “Probucol attenuates cyclophosphamideinduced oxidative apoptosis, p53 and Bax signal expression in rat cardiac tissues,” Oxidative Medicine and Cellular Longevity, vol. 3, no. 5, pp. 308–316, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. I. B. Fritz and E. Arrigoni-Martelli, “Sites of action of carnitine and its derivatives on the cardiovascular system: interactions with membranes,” Trends in Pharmacological Sciences, vol. 14, no. 10, pp. 355–360, 1993. View at Publisher · View at Google Scholar · View at Scopus
  48. M. M. Sayed-Ahmed, S. A. Shouman, B. M. Rezk, M. H. Khalifa, A. M. M. Osman, and M. M. El-Merzabani, “Propionyl-L-carnitine as potential protective agent against adriamycin-induced impairment of fatty acid beta-oxidation in isolated heart mitochondria,” Pharmacological Research, vol. 41, no. 2, pp. 143–150, 2000. View at Publisher · View at Google Scholar · View at Scopus
  49. M. M. Sayed-Ahmed, M. M. Khattab, M. Z. Gad, and N. Mostafa, “L-carnitine prevents the progression of atherosclerotic lesions in hypercholesterolaemic rabbits,” Pharmacological Research, vol. 44, no. 3, pp. 235–242, 2001. View at Publisher · View at Google Scholar · View at Scopus
  50. A. A. Al-Majed, M. M. Sayed-Ahmed, F. A. Al-Omar, A. A. Al-Yahya, A. M. Aleisa, and O. A. Al-Shabanah, “Carnitine esters prevent oxidative stress damage and energy depletion following transient forebrain ischaemia in the rat hippocampus,” Clinical and Experimental Pharmacology and Physiology, vol. 33, no. 8, pp. 725–733, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. A. Augustyniak and E. Skrzydlewska, “The influence of L-carnitine suplementation on the antioxidative abilities of serum and the central nervous system of ethanol-induced rats,” Metabolic Brain Disease, vol. 25, no. 4, pp. 381–389, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. F. Bodea, A. Bocea, and N. Decea, “L-carnitine decreases oxidative stress induced by experimental hypobaric hypoxia,” Pediatric Endocrinology, Diabetes, and Metabolism, vol. 16, no. 2, pp. 78–81, 2010. View at Google Scholar · View at Scopus
  53. J. Liu, “The effects and mechanisms of mitochondrial nutrient α-lipoic acid on improving age-associated mitochondrial and cognitive dysfunction: an overview,” Neurochemical Research, vol. 33, no. 1, pp. 194–203, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. H. H. Chen, Y. M. Sue, C. H. Chen et al., “Peroxisome proliferator-activated receptor alpha plays a crucial role in l-carnitine anti-apoptosis effect in renal tubular cells,” Nephrology Dialysis Transplantation, vol. 24, no. 10, pp. 3042–3049, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. S. Y. Ozsoy, B. Ozsoy, Z. Ozyildiz, and I. Aytekin, “Protective effect of L-carnitine on experimental lead toxicity in rats: a clinical, histopathological and immunohistochemical study,” Biotechnic and Histochemistry, vol. 86, no. 6, pp. 436–443, 2010. View at Google Scholar
  56. K. L. Goa and R. N. Brogden, “l-Carnitine: a preliminary review of its pharmacokinetics, and its therapeutic use in ischaemic cardiac disease and primary and secondary carnitine deficiencies in relationship to its role in fatty acid metabolism,” Drugs, vol. 34, no. 1, pp. 1–24, 1987. View at Google Scholar · View at Scopus
  57. X. Luo, B. Reichetzer, J. Trines, L. N. Benson, and D. C. Lehotay, “L-carnitine attenuates doxorubicin-induced lipid peroxidation in rats,” Free Radical Biology and Medicine, vol. 26, no. 9-10, pp. 1158–1165, 1999. View at Publisher · View at Google Scholar · View at Scopus
  58. Y. Campos, R. Huertas, G. Lorenzo et al., “Plasma carnitine insufficiency and effectiveness of L-carnitine therapy in patients with mitochondrial myopathy,” Muscle and Nerve, vol. 16, no. 2, pp. 150–153, 1993. View at Publisher · View at Google Scholar · View at Scopus
  59. H. Bohles, A. Evangeliou, K. Bervoets, I. Eckert, and A. Sewell, “Carnitine esters in metabolic disease,” European Journal of Pediatrics, vol. 153, no. 1, pp. S57–S61, 1994. View at Publisher · View at Google Scholar · View at Scopus
  60. S. C. Winter, E. M. Zorn, and W. H. Vance, “Carnitine deficiency,” Lancet, vol. 335, no. 8695, pp. 981–982, 1990. View at Google Scholar · View at Scopus
  61. J. R. Neely and H. E. Morgan, “Relationship between carbohydrate and lipid metabolism and the energy balance of heart muscle,” Annual Review of Physiology, vol. 36, pp. 413–459, 1974. View at Google Scholar · View at Scopus
  62. A. Koc, M. Duru, H. Ciralik, R. Akcan, and S. Sogut, “Protective agent, erdosteine, against cisplatin-induced hepatic oxidant injury in rats,” Molecular and Cellular Biochemistry, vol. 278, no. 1-2, pp. 79–84, 2005. View at Publisher · View at Google Scholar · View at Scopus
  63. A. Tiersten, J. Wo, C. Jacobson et al., “Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer,” Breast, vol. 13, no. 4, pp. 341–346, 2004. View at Publisher · View at Google Scholar · View at Scopus
  64. E. Selvakumar, C. Prahalathan, P. T. Sudharsan, and P. Varalakshmi, “Protective effect of lipoic acid on cyclophosphamide-induced testicular toxicity,” Clinica Chimica Acta, vol. 367, no. 1-2, pp. 114–119, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. S. A. Kumar, V. Sudhahar, and P. Varalakshmi, “Protective role of eicosapentaenoate-lipoate (EPA-LA) derivative in combating oxidative hepatocellular injury in hypercholesterolemic atherogenesis,” Atherosclerosis, vol. 189, no. 1, pp. 115–122, 2006. View at Publisher · View at Google Scholar · View at Scopus